Get the Stockscreener App
3.26
9.40%
0.28
After Hours:
3.60
0.34
+10.43%
An 2 Therapeutics Inc stock is traded at $3.26, with a volume of 1.04M.
It is up +9.40% in the last 24 hours and down -34.01% over the past month.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
See More
Previous Close:
$2.98
Open:
$2.91
24h Volume:
1.04M
Relative Volume:
0.80
Market Cap:
$117.19M
Revenue:
-
Net Income/Loss:
$-35.17M
P/E Ratio:
-2.80
EPS:
-1.1643
Net Cash Flow:
$-29.83M
1W Performance:
-2.40%
1M Performance:
-34.01%
6M Performance:
+165.04%
1Y Performance:
+158.73%
1-Day Range:
$2.872
$3.27
1-Week Range:
$2.872
$3.35
52-Week Range:
$1.00
$6.9099
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Name
An 2 Therapeutics Inc
Sector
Industry
Phone
(650) 331-9090
Address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Compare ANTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
3.26 | 107.13M | 0 | -35.17M | -29.83M | -1.1643 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-24 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-03-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Apr-02-24 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-13-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-12-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-12-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-12-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
View All
An 2 Therapeutics Inc Stock (ANTX) Latest News
Allogene Therapeutics, Inc. Files Form 8-K Current Report with SEC on April 13, 2026 2 - Minichart
ALLO Stock Jumps As Pivotal ALPHA3 CAR-T Data Loom - StocksToTrade
After layoffs, biotech exits 2 Boston-area leases - NBC Boston
AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT - GlobeNewswire
INVESTOR ALERT: Soleno Therapeutics Inc. (SLNO) Investors - GlobeNewswire
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at 25th Annual Needham Virtual Healthcare Conference - Quiver Quantitative
United Therapeutics Soars as Clinical Trials Meet Key Endpoints - StocksToTrade
Plus Therapeutics, Inc. Announces 1-for-25 Reverse Stock Split Effective April 2, 2026 | PSTV Stock News - Quiver Quantitative
To keep its Nasdaq listing, Plus Therapeutics enacts 1-for-25 split - Stock Titan
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease - Business Wire
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha
Protara Therapeutics (TARA) sustains 68% CR in ADVANCED-2 and activates $5.25 warrants - Stock Titan
Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin DeficiencySlideshow (NASDAQ:BEAM) 2026-03-27 - Seeking Alpha
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 - Finviz
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1Slideshow (NASDAQ:SRPT) 2026-03-25 - Seeking Alpha
Denali Therapeutics Inc.: Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - FinanzNachrichten.de
Maze Therapeutics (Nasdaq: MAZE) posts positive Phase 2 MZE829 data and ends 2025 with $360M cash - Stock Titan
Apogee Therapeutics Sees Price Target Boost Amid Clinical Progress - StocksToTrade
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire
Dementia trial drug slowed neuropsychiatric decline 86% vs placebo - stocktitan.net
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1Slideshow (NASDAQ:GPCR) 2026-03-16 - Seeking Alpha
Relay Therapeutics (RLAY) shows 11.1-month PFS with zovegalisib combo in PI3Kα-mutated breast cancer - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) shows 16% weight loss in Phase 2 oral GLP-1 trial - Stock Titan
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study - PR Newswire
Inhaled IPF drug from United Therapeutics slows lung scarring in trial - Stock Titan
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings - AlphaStreet
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. - Yahoo Finance
Trevi Therapeutics Announces Completion of End-of-Phase 2 - GlobeNewswire
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - BioSpace
Drug film BXCL501 eases opioid withdrawal in Columbia University study - Stock Titan
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - BioSpace
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Intellia Therapeutics
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory - Insider Monkey
Heron Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
CAD-1005 Phase 2 data spur FDA EOP2 talks for Cadrenal (NASDAQ: CVKD) - Stock Titan
Cadrenal Therapeutics Announces Phase 2 Results with - GlobeNewswire
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma - GlobeNewswire
VA-funded Phase 2 stenoparib trial begins for Allarity (NASDAQ: ALLR) - Stock Titan
Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks - Yahoo Finance
VA lung cancer trial tests new drug combo for patients with few options - Stock Titan
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress - Insider Monkey
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans - Benzinga
TSX Insights Medicenna Therapeutics And 2 Other Promising Penny Stocks - Yahoo Finance
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 earnings call transcript - MSN
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - PR Newswire
Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide - GlobeNewswire
Assessing Structure Therapeutics (GPCR) Valuation As GSBR-1290 Advances Through Phase 2 Obesity Trials - Yahoo Finance
Gain Therapeutics, Inc Advances Parkinson's Treatment to Phase 2 - TradingView
Sangamo Therapeutics IncOn Feb 2, Prathyusha Duraibabu terminated as principal financial officerSEC filing - marketscreener.com
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - GlobeNewswire
An 2 Therapeutics Inc Stock (ANTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):